The abstract is read at the publisher; the summary is JClub's.
RAC1 is hyperactivated downstream of constitutively active TIE2-L914F in human endothelial cells, and RAC1 inhibition reduces aberrant vascular lumen area and migration.
- Why it matters: Mutant TIE2 in venous malformations is linked to PI3K/AKT dysregulation, but the downstream pathway driving enlarged lumens and endothelial dysfunction is unclear.
- What they did: HUVECs expressing wild-type TIE2 or TIE2-L914F were tested with RAC1 GTP pull-down, immunoblotting, and 2D/3D endothelial functional assays, with RAC1 blocked by NSC23766 in vitro and in a TIE2-L914F xenograft model.
- The result: RAC1 activation by TIE2-L914F is PI3K-dependent but not MEK/ERK-dependent, and RAC1 inhibition attenuates cytoskeletal changes, migration, and xenograft lesion formation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.